Novo Nordisk's agreement to cap insulin prices for uninsured New Yorkers at $35 per monthly prescription for the next 5 years could potentially reduce its revenue from this segment. This is because the company may not be able to increase prices in response to rising costs or inflation, which could squeeze margins. However, the impact may be mitigated if the price cap leads to increased volume of sales.